Pancreatic

KRAS ctDNA Is Predictor of Metastasis and Survival in Pancreatic Cancer

A Mayo Clinic study found that detecting KRAS ctDNA in pancreatic cancer patients signals a higher risk of cancer spread and poorer survival.

Pancreatic

Pancreatic Cancer Test Is Surveillance Tool for High-Risk Patients

ClearNote Health says its Avantect Pancreatic Cancer test is effective for managing new-onset diabetes patients' risk of developing cancer.

Pancreatic

Pancreatic Cancer Test Gets CPT Code, Preliminary Payment Determination from the CMS

The AMA issued a new Current Procedural Terminology (CPT) Proprietary Laboratory Analyses (PLA) code for the Avantect Pancreatic Cancer Test.

Bluestar Genomics’ Pancreatic Cancer Detection Test Achieves High Sensitivity & Specificity

Nov 2, 2022 | Pancreatic

Bluestar Genomics announced the results of a validation study for its early pancreatic cancer detection test.

Pancreatic Cancer Could be Diagnosed up to Three Years Earlier

Nov 1, 2022 | Pancreatic

Pancreatic cancer could be identified in patients up to three years earlier than current diagnoses, new research suggests.

Bluestar Genomics Receives CAP Accreditation for its Clinical Lab

Oct 10, 2022 | Accreditation, Pancreatic

The CAP certification enables Bluestar to serve physicians as it works towards broad commercialization of its pancreatic cancer test.

PancreaSeq Molecular Test Outperforms Current Guidelines

Oct 5, 2022 | Pancreatic, Sequencing Systems

The PancreaSeq molecular test accurately classifies pancreatic cysts as potentially cancerous or benign, a large, multi-center study found.

Personalis & BC Cancer Assess Benefits of ctDNA for Colorectal, Pancreatic Cancers

Aug 15, 2022 | Colorectal, Pancreatic

Personalis and BC Cancer will deploy a personalized liquid biopsy-based assay for a study of patients with colorectal and pancreatic cancers.

Researchers Discover Molecular Switch in Pancreatic Cancer that Triggers Metastasis

Jun 28, 2022 | Pancreatic

Pancreatic ductal adenocarcinoma affects more than 90% of patients with pancreatic cancer and has an average 5-year survival rate under 10%.

Stool Sample Microorganisms Could Help Detect Pancreatic Cancer Early

Mar 10, 2022 | Pancreatic

Researchers have found a molecular signature in stool samples that could predict whether patients are at high risk of pancreatic cancer.

Researchers May Have Found Diagnostic Game Changer for Pancreatic Cancer

Nov 17, 2021 | Pancreatic

Yale Cancer Center early detection research is providing new reason for optimism for the diagnosis of pancreatic cancer.

Liquid Biopsy Test Detects Pancreatic Cancer Signal

Nov 9, 2021 | Pancreatic

Bluestar Genomics’ liquid biopsy test can detect a pancreatic cancer signal in people across various age groups and in patients with new-onset diabetes.

Blood Test May Be Future of Pancreatic Cancer Detection

Oct 5, 2021 | Pancreatic

New research showed that blood tests may be the future of pancreatic cancer detection. Pancreatic cancer is one of the most deadly forms of the disease.

New Genetic Targets Could Revolutionize Early Pancreatic Cancer Detection

Sep 27, 2021 | Mass Spectrometry Instruments, Molecular Diagnostics, Pancreatic

Researchers from Johns Hopkins and an international team, have identified promising new targets for pancreatic cancer treatment and early diagnosis.

Study: PTX3 Biomarker Could Aid in Pancreatic Cancer Diagnosis

Jun 29, 2021 | Pancreatic

Researchers from Queen Mary University of London have identified a protein that could be used to aid in the diagnosis of pancreatic cancer.

Pancreatic Cancer Action Network Increases Biomarker-Driven Clinical Trial Matching by Nearly 300% with GenomOncology

Jun 25, 2021 | Pancreatic

PanCAN has chosen to upgrade to GenomOncology’s Precision Decision to further enhance the free clinical trial matching services it offers to pancreatic cancer patients.